- Home
- APLM vs CHRO Comparison
APLM vs CHRO Comparison
Compare APLM & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- CHRO
- Stock Information
- Founded
- APLM 2016
- CHRO 2002
- Country
- APLM United States
- CHRO United States
- Employees
- APLM N/A
- CHRO N/A
- Industry
- APLM Blank Checks
- CHRO
- Sector
- APLM Finance
- CHRO
- Exchange
- APLM Nasdaq
- CHRO Nasdaq
- Market Cap
- APLM 7.7M
- CHRO 8.1M
- IPO Year
- APLM N/A
- CHRO 2024
- Fundamental
- Price
- APLM $6.51
- CHRO $1.37
- Analyst Decision
- APLM Strong Buy
- CHRO Strong Buy
- Analyst Count
- APLM 1
- CHRO 1
- Target Price
- APLM $200.00
- CHRO N/A
- AVG Volume (30 Days)
- APLM 57.8K
- CHRO 2.1M
- Earning Date
- APLM 04-03-2025
- CHRO 05-14-2025
- Dividend Yield
- APLM N/A
- CHRO N/A
- EPS Growth
- APLM N/A
- CHRO N/A
- EPS
- APLM N/A
- CHRO N/A
- Revenue
- APLM $198,000.00
- CHRO N/A
- Revenue This Year
- APLM $415.15
- CHRO N/A
- Revenue Next Year
- APLM N/A
- CHRO N/A
- P/E Ratio
- APLM N/A
- CHRO N/A
- Revenue Growth
- APLM N/A
- CHRO N/A
- 52 Week Low
- APLM $4.71
- CHRO $0.45
- 52 Week High
- APLM $53.00
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- APLM 49.37
- CHRO 46.67
- Support Level
- APLM $5.41
- CHRO $1.29
- Resistance Level
- APLM $6.19
- CHRO $1.65
- Average True Range (ATR)
- APLM 0.77
- CHRO 0.20
- MACD
- APLM 0.08
- CHRO 0.02
- Stochastic Oscillator
- APLM 95.24
- CHRO 13.81
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.